TAISHO PHARMACEUTICAL HOLDINGS CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12 USD | 0.00% |
|
0.00% | -18.97% |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,42,424 | 5,40,582 | 5,75,028 | 4,63,937 | 4,52,020 | 6,09,220 | - | - |
| Enterprise Value (EV) 1 | 4,83,957 | 3,02,679 | 3,20,833 | 1,91,669 | 1,95,854 | 6,09,220 | 6,09,220 | 6,09,220 |
| P/E ratio | - | - | - | - | - | - | - | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.22 x | 1.87 x | 2.04 x | 1.73 x | 1.5 x | 1.87 x | 1.82 x | 1.76 x |
| EV / Revenue | 3.22 x | 1.87 x | 2.04 x | 1.73 x | 1.5 x | 1.87 x | 1.82 x | 1.76 x |
| EV / EBITDA | 19.8 x | 14.2 x | 13.7 x | 13.7 x | 9.48 x | 11.7 x | 10.7 x | 10.2 x |
| EV / FCF | 60.8 x | -8.31 x | 21.4 x | 21.6 x | 32.7 x | 13.1 x | 10.7 x | - |
| FCF Yield | 1.64% | -12% | 4.67% | 4.62% | 3.06% | 7.61% | 9.33% | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 3,19,267 | 3,19,260 | 3,19,267 | 3,27,946 | 3,27,923 | 3,27,870 | - | - |
| Reference price 2 | 23.81 | 15.75 | 16.26 | 11.62 | 10.38 | 12.00 | 12.00 | 12.00 |
| Announcement Date | 13/05/19 | 14/05/20 | 14/05/21 | 13/05/22 | 11/05/23 | - | - | - |
1USD in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,61,551 | 2,88,527 | 2,81,980 | 2,68,203 | 3,01,381 | 3,25,000 | 3,34,900 | 3,45,900 |
| EBITDA 1 | 42,501 | 38,155 | 42,006 | 33,817 | 47,666 | 52,250 | 57,200 | 59,850 |
| EBIT 1 | 31,211 | 21,460 | 19,965 | 10,743 | 23,018 | 24,500 | 29,150 | 31,500 |
| Operating Margin | 11.93% | 7.44% | 7.08% | 4.01% | 7.64% | 7.54% | 8.7% | 9.11% |
| Earnings before Tax (EBT) | 64,484 | 30,311 | 22,976 | 21,398 | 29,498 | - | - | - |
| Net income 1 | 48,593 | 20,531 | 13,316 | 13,122 | 18,997 | 14,400 | 20,600 | 22,200 |
| Net margin | 18.58% | 7.12% | 4.72% | 4.89% | 6.3% | 4.43% | 6.15% | 6.42% |
| EPS | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 13,848 | -65,089 | 26,826 | 21,443 | 13,842 | 46,380 | 56,850 | - |
| FCF margin | 5.29% | -22.56% | 9.51% | 8% | 4.59% | 14.27% | 16.98% | - |
| FCF Conversion (EBITDA) | 32.58% | - | 63.86% | 63.41% | 29.04% | 88.77% | 99.39% | - |
| FCF Conversion (Net income) | 28.5% | - | 201.46% | 163.41% | 72.86% | 322.08% | 275.97% | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 13/05/19 | 14/05/20 | 14/05/21 | 13/05/22 | 11/05/23 | - | - | - |
1JPY in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2021 S1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,32,208 | 1,45,900 | 66,277 | 1,30,161 | 69,890 | 68,152 | 69,069 | 75,449 | 1,44,518 | 83,151 | 73,712 | 80,802 | 82,295 | 1,63,097 | 83,576 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 14,676 | 16,295 | -363 | 2,313 | 4,820 | 3,610 | 5,254 | 6,953 | 12,207 | 10,917 | -106 | 9,073 | 7,287 | 16,360 | 2,657 |
| Operating Margin | 11.1% | 11.17% | -0.55% | 1.78% | 6.9% | 5.3% | 7.61% | 9.22% | 8.45% | 13.13% | -0.14% | 11.23% | 8.85% | 10.03% | 3.18% |
| Earnings before Tax (EBT) 1 | 20,954 | 18,393 | - | 6,269 | 9,244 | - | 9,210 | 8,064 | 17,274 | 12,626 | -402 | 7,098 | 5,924 | 13,022 | 4,464 |
| Net income 1 | 14,979 | 11,294 | - | 2,908 | 6,066 | - | 5,751 | 5,126 | 10,877 | 10,022 | -1,902 | 4,363 | 3,087 | 7,450 | 2,873 |
| Net margin | 11.33% | 7.74% | - | 2.23% | 8.68% | - | 8.33% | 6.79% | 7.53% | 12.05% | -2.58% | 5.4% | 3.75% | 4.57% | 3.44% |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 30/10/19 | 29/10/20 | 09/11/21 | 09/11/21 | 01/02/22 | 13/05/22 | 03/08/22 | 10/11/22 | 10/11/22 | 09/02/23 | 11/05/23 | 04/08/23 | 10/11/23 | 10/11/23 | 13/02/24 |
1JPY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 3,58,467 | 2,37,903 | 2,54,195 | 2,72,268 | 2,56,166 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 13,848 | -65,089 | 26,826 | 21,443 | 13,842 | 46,380 | 56,850 | - |
| ROE (net income / shareholders' equity) | 7% | 2.9% | 1.9% | 1.8% | 2.5% | 1.8% | 2.5% | - |
| ROA (Net income/ Total Assets) | 5.04% | 2.99% | 3% | 2.09% | 3.33% | 1.5% | 2.1% | - |
| Assets 1 | 9,64,664 | 6,87,444 | 4,43,929 | 6,28,975 | 5,70,849 | 9,60,000 | 9,80,952 | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 5,374 | 9,596 | 15,200 | 16,925 | 53,959 | 17,000 | 17,500 | - |
| Capex / Sales | 2.05% | 3.33% | 5.39% | 6.31% | 17.9% | 5.23% | 5.23% | - |
| Announcement Date | 13/05/19 | 14/05/20 | 14/05/21 | 13/05/22 | 11/05/23 | - | - | - |
1JPY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TAIPY Stock
- Financials Taisho Pharmaceutical Holdings Co., Ltd.
